Welcome to our dedicated page for Janux Therapeutics SEC filings (Ticker: JANX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Janux Therapeutics, Inc. (Nasdaq: JANX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including current reports on Form 8-K and other periodic filings. As a clinical-stage biopharmaceutical company focused on tumor-activated immunotherapies, Janux uses these filings to report financial results, business updates and certain corporate events.
Form 8-K filings for Janux include items such as the public release of quarterly financial results under Item 2.02, where the company furnishes press releases summarizing collaboration revenue, research and development expenses, general and administrative expenses, and net loss for specific reporting periods. Other 8-Ks address corporate matters under Item 5.02, such as changes in executive roles or departures of certain officers, along with references to relevant compensation or severance arrangements.
For investors analyzing JANX, the full SEC record also encompasses annual reports on Form 10-K, quarterly reports on Form 10-Q, and any registration statements or proxy materials the company may file. These documents typically provide details on the TRACTr, TRACIr and ARM platforms, risk factors related to clinical development, descriptions of the JANX007 and JANX008 clinical programs, and information on collaborations, including the TRACTr agreement with Merck.
On Stock Titan, Janux filings are updated as new documents are posted to EDGAR, and each entry can be paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to earnings, pipeline updates, or corporate governance, and can review the underlying text when deeper due diligence is required. This page also provides a convenient route to track any future insider transaction reports on Form 4, as well as proxy statements that may discuss executive compensation and governance policies.
Janux Therapeutics entered an exclusive license and collaboration agreement with Bristol-Myers Squibb to develop and commercialize a novel tumor-activated therapeutic for solid tumors. Janux will handle preclinical work through IND submission for one drug candidate, after which BMS will take over global development, manufacturing and commercialization, while Janux supplies product for early clinical trials for a limited period.
Janux receives a $15 million upfront payment and may earn up to $785 million in development, regulatory and sales milestones, including $35 million tied to a near-term milestone. BMS will also pay tiered royalties from high-single digit to low-double digit percentages on annual net sales of any approved products, with royalty terms linked to patent life, regulatory exclusivity and time from first commercial sale.
FMR LLC and Abigail P. Johnson filed Amendment No. 4 to a Schedule 13G/A reporting their beneficial ownership of common stock of Janux Therapeutics Inc. As of the event date of 12/31/2025, they report beneficial ownership of 3,512,384 shares of common stock, representing 5.8% of the class. FMR LLC has sole voting power over 3,505,856 shares and sole dispositive power over 3,512,384 shares, while Abigail P. Johnson reports sole dispositive power over the same 3,512,384 shares.
The filing states that one or more other persons have the right to receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the outstanding common stock. The securities are described as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Janux Therapeutics.
Janux Therapeutics (JANX) reported an insider equity transaction by its Chief Business Officer. On 11/14/2025, the officer exercised a stock option for 3,333 shares of common stock at $10.59 per share and on the same date sold 3,333 shares at $30 per share. After these transactions, the officer beneficially owned 84,974 shares of Janux common stock directly and 118,101 stock options. The sale was conducted under a Rule 10b5-1 trading plan adopted on 09/30/2024. The filing also notes prior acquisitions of 1 share on 11/15/2024 and 2,834 shares on 05/15/2025 through the company’s 2021 Employee Stock Purchase Plan.
Janux Therapeutics (JANX) reported Q3 2025 results. Collaboration revenue reached $10,000 (vs. $439 in Q3 2024), driven by a $10.0 million Merck milestone achieved in August tied to the first collaboration target. R&D expense was $34,629 and G&A was $10,622, leading to a net loss of $24,313, or $0.39 per share.
For the nine months, revenue totaled $10,000, operating expenses were $125,266, and net loss was $81,679. Interest income contributed $33,587 year-to-date. Cash and cash equivalents were $48,389 and short‑term investments were $940,604 as of September 30, supporting total assets of $1,024,766. Net cash used in operating activities was $53,693 for the period. Shares outstanding were 60,123,602 at quarter end; 60,147,807 were outstanding as of November 4, 2025.
The company states it has sufficient capital to fund operations for at least 12 months. Performance obligations under the Merck collaboration were completed as of September 30, 2025, with future milestones recognized only upon occurrence.
Janux Therapeutics, Inc. filed a current report to note that it released a press release with its financial results for the three and nine months ended September 30, 2025. The company is furnishing, not filing, this information, which means the press release is not subject to certain liability provisions under the securities laws and is not automatically incorporated into other SEC filings. Investors interested in the detailed revenue, expense, and earnings figures for this period would need to review the attached Exhibit 99.1 press release referenced in the report.
Janux Therapeutics (JANX) Form 4: The company’s Chief Business Officer reported two option exercises and a subsequent sale on 10/28/2025. He exercised 9,999 options at $4.21 and 6,666 options at $10.59, then sold 16,665 shares.
The sale’s weighted average price was $30.0622, with trades between $30.00 and $30.49, executed under a Rule 10b5-1 trading plan adopted on September 30, 2024. Following these transactions, he directly beneficially owned 82,139 shares.
Janux Therapeutics, Inc. reported that Byron Robinson, Ph.D., a previously named executive officer, has left the company. He ceased serving as Chief Strategy Officer and departed effective September 18, 2025. The company determined that his departure qualifies as a termination without “Cause” under its Change in Control and Severance Benefit Plan, which may entitle him to certain severance benefits pursuant to that plan. The filing does not announce any new appointment to the Chief Strategy Officer role.
Paradigm BioCapital and related parties disclosed ownership stakes in Janux Therapeutics common stock totaling up to 2,920,258 shares, representing 4.9% of the outstanding shares. The filing identifies four reporting persons: Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., with the Fund separately reported as holding 2,593,376 shares (4.4%). The ownership figures are stated as of the June 30, 2025 event date and are calculated using 59,175,157 shares outstanding as of May 6, 2025. The filers certify the positions were not acquired to change or influence control of the issuer.
Janus Henderson Group plc reports a passive institutional stake in Janux Therapeutics, Inc. common stock. The filing lists an aggregate beneficial ownership of 4,460,332 shares (7.5% of the class) attributed to the reporting person, while Item 4 separately identifies JHIUS as the beneficial owner of 4,379,232 shares (7.4%). The report shows shared voting and dispositive power over the shares and classifies the reporting person with reporting types IA and HC.
The filing states the shares are held in the ordinary course of business and not with the purpose of changing or influencing issuer control, and discloses that JHIUS, JHIUKL and JHIAIFML are indirect subsidiaries acting as registered investment advisers to managed portfolios.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 2,525,000 shares of Janux Therapeutics common stock, equal to 4.27% of the company based on 59,175,157 shares outstanding as of May 6, 2025. The shares are directly held by Adage Capital Partners, L.P., and the cover data shows shared voting power and shared dispositive power for the full 2,525,000 shares and no sole voting or dispositive power.
The filing states these securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The reporting persons list their principal business office at 200 Clarendon Street, 52nd Floor, Boston, Massachusetts, and identify ACM as Delaware organized and Messrs. Atchinson and Gross as U.S. citizens.